These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20829677)

  • 1. How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision.
    Kaldor JM; Wilson DP
    AIDS; 2010 Oct; 24(16):2573-8. PubMed ID: 20829677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
    Schneider K; Kerr CC; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.
    Nagelkerke NJ; Hontelez JA; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6079-85. PubMed ID: 21718745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
    Gray RT; Ghaus MH; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adult circumcision in a resource-rich setting for HIV prevention among men who have sex with men.
    Anderson J; Wilson D; Templeton DJ; Grulich A; Carter R; Kaldor J
    J Infect Dis; 2009 Dec; 200(12):1803-12. PubMed ID: 19909084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
    Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
    Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
    Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA.
    Verguet S; Walsh JA
    Sex Transm Infect; 2010 Jun; 86(3):212-6. PubMed ID: 20522634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
    Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
    Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda.
    Gray RH; Li X; Kigozi G; Serwadda D; Nalugoda F; Watya S; Reynolds SJ; Wawer M
    AIDS; 2007 Apr; 21(7):845-50. PubMed ID: 17415039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Male circumcision: hope for HIV infection decrease in southern Africa].
    Legeai C; Auvert B
    Med Sci (Paris); 2008 May; 24(5):499-504. PubMed ID: 18466727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances.
    Bansal GP; Malaspina A; Flores J
    Curr Opin Mol Ther; 2010 Feb; 12(1):39-46. PubMed ID: 20140815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
    Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
    Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The private demand for an AIDS vaccine in Thailand.
    Suraratdecha C; Ainsworth M; Tangcharoensathien V; Whittington D
    Health Policy; 2005 Mar; 71(3):271-87. PubMed ID: 15694496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent efforts in biomedical prevention of HIV.
    Landovitz RJ
    Top HIV Med; 2007; 15(3):99-103. PubMed ID: 17598929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV vaccine research in Thailand: lessons learned.
    Pitisuttithum P
    Expert Rev Vaccines; 2008 Apr; 7(3):311-7. PubMed ID: 18393601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.
    Andersson KM; Paltiel AD; Owens DK
    Vaccine; 2011 Aug; 29(36):6107-12. PubMed ID: 21736912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costing adult male circumcision in high HIV prevalence, low circumcision rate countries.
    Fieno JV
    AIDS Care; 2008 May; 20(5):515-20. PubMed ID: 18484318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.